具有协同抗瘤活性和增强膜透性的Pt(IV) -PROTAC复合体.
Cheng-Xin Li1,2, Zhi-Ru Zou1,2, Shan Xu1,2
1State Key Laboratory of Anti-Infective Drug Discovery and Development, Sun Yat-sen University, Guangzhou 510006, China.
新的-IV-PROTAC复合物诱导DNA损伤并抑制DNA修复,显示出强大的抗癌活性. 化合物CW-2在临床前模型中显示出显著的抗瘤作用,突出显示出一个有前途的治疗策略.
科学领域:
- 药用化学 医学化学
- 癌症生物学 癌症生物学
- 药物发现 药物发现 药物发现
背景情况:
- 基于的化疗仍然是癌症治疗的基石.
- 开发具有提高疗效和降低耐药性的新复合物至关重要.
- 针对性药物输送系统,如PROTACs,为增强癌症治疗提供了潜力.
研究的目的:
- 设计和合成新的 (IV) - PROTAC复合物.
- 评估它们在诱导DNA损伤和抑制DNA修复方面的双重作用.
- 评估它们的抗增殖和抗瘤潜力.
主要方法:
- 合成和表征Pt(IV) - PROTAC复合体.
- 针对各种癌症细胞系的体外抗增殖试验.
- 细胞内和PROTAC吸收的评估.
- 机理学研究包括DNA损伤,DNA修复抑制和亡试验.
- 在异种移植小鼠模型中的体内抗瘤疗效评估.
主要成果:
- 成功合成了新的Pt(IV) - PROTAC复合体.
- 这些复合体对癌细胞表现出显著的抗增殖活性.
- 观察到白金和PROTAC成分的细胞内吸收增加.
- 机制包括DNA损伤诱导,DNA修复中断和亡.
- 化合物CW-2在体内表现出卓越的抗瘤活性.
结论:
- Pt(IV) -PROTAC复合体代表了一种有前途的新型抗癌药物.
- 它们的双重作用机制增强了治疗潜力.
- 进一步开发Pt(IV) -PROTACs可能会导致新的抗瘤疗法.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
相关概念视频
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Drugs that Stabilize Microtubules
